//Reference=Talairach
//GA coordinates
//STUDYID 	ANANTH 2002		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 2. REGIONAL DIFFERENCES IN GRAY AND WHITE MATTER VOLUME BETWEEN 20 PATIENTS WITH SCHIZOPHRENIA AND 20 MATCHED COMPARISON SUBJECTS 		
//CONDITIONID  			
//CONTRASTID  			
//controls=20
//subjects=20
-8.000000 -15.000000 17.000000 
45.000000 -74.000000 18.000000 
2.000000 63.000000 14.000000 
42.000000 -5.000000 65.000000 
66.000000 -35.000000 -6.000000 
-23.000000 -74.000000 -9.000000 
-6.000000 -75.000000 18.000000 
47.000000 -20.000000 68.000000 
23.000000 38.000000 53.000000 
51.000000 -69.000000 38.000000 
-45.000000 15.000000 36.000000 
-39.000000 -5.000000 68.000000 
30.000000 33.000000 -9.000000 

//STUDYID 	ANTONOVA 2005		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	COORDINATES IN TEXT		
//CONDITIONID  			
//CONTRASTID  			
//controls=43
//subjects=45
-33.000000 27.000000 -8.000000 
-22.000000 -86.000000 -9.000000 

//STUDYID 	ASAMI 2012		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	SUPPLEMENTAL TABLE S1		
//CONDITIONID  			
//CONTRASTID  			
//controls=23
//subjects=21
-40.327499 -10.081400 -2.917300 
-38.334900 2.052000 -12.754700 
-29.027100 -9.433400 -11.760700 
6.363500 35.984402 31.995899 
-1.111700 -14.838800 6.181500 
-6.949100 -82.596199 2.498700 

//STUDYID 	BASSITT 2007		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	COORDINATES IN TEXT		
//CONDITIONID  			
//CONTRASTID  			
//controls=30
//subjects=50
54.000000 10.000000 8.000000 
-42.000000 6.000000 12.000000 
56.000000 -5.000000 3.000000 
-38.000000 1.000000 12.000000 

//STUDYID 	CASCELLA 2010		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 2 HCNSZ (COVARIATES: AGE  SEX AND TICV); FWE PB.05; ET=20		
//CONDITIONID  			
//CONTRASTID  			
//controls=90
//subjects=50
-34.000000 34.000000 -18.000000 
38.000000 20.000000 -14.000000 
-52.000000 8.000000 18.000000 
24.000000 40.000000 44.000000 
-2.000000 30.000000 42.000000 
-4.000000 54.000000 2.000000 
-58.000000 2.000000 -22.000000 
-40.000000 20.000000 -8.000000 
-32.000000 -8.000000 -46.000000 
8.000000 -70.000000 40.000000 
2.000000 -92.000000 6.000000 
52.000000 -60.000000 -18.000000 

//STUDYID 	CHUA	2006										
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=2.650000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE	3	REGIONAL	GREY	AND	WHITE	MATTER	DEFICITS	IN	FEP	(PB0.004)	
//CONDITIONID  												
//CONTRASTID  												
//controls=38
//subjects=26
2.600000 14.000000 1.000000 
1.400000 -48.200001 25.000000 
28.100000 8.500000 -19.600000 
-17.500000 0.300000 -22.500000 
-36.099998 3.900000 0.900000 
39.299999 -0.600000 3.400000 
-55.700001 3.900000 -4.600000 
-4.600000 -49.700001 -21.799999 
28.299999 -42.700001 -33.200001 
2.100000 -46.299999 37.799999 

//STUDYID 	DONOHOE 2011		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	SUPPLEMENTAL TABLE S1		
//CONDITIONID  			
//CONTRASTID  			
//controls=38
//subjects=70
-0.392000 -17.023300 33.092800 
-45.120201 -31.228300 1.653700 
19.341900 14.641400 37.659302 
11.017600 -26.198500 5.413000 
-56.534302 -30.291700 25.966600 
28.726000 3.015000 28.714399 
-13.315000 -29.715300 3.947700 
22.021700 -13.062100 40.889599 
7.590400 53.479900 2.721600 
-21.945999 -7.191600 41.753399 

//STUDYID 	GIULIANI 2005		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 2 SUMMARY OF AREAS DETECTED IN THE MAIN EFFECTS ANALYSES		
//CONDITIONID  			
//CONTRASTID  			
//controls=34
//subjects=41
-13.000000 56.000000 -8.000000 
22.000000 59.000000 5.000000 
-56.000000 23.000000 3.000000 
45.000000 16.000000 -3.000000 
-3.000000 8.000000 -11.000000 
-67.000000 -9.000000 14.000000 
-49.000000 10.000000 -2.000000 
46.000000 10.000000 -2.000000 
-46.000000 13.000000 -7.000000 
45.000000 10.000000 -4.000000 
-1.000000 4.000000 -4.000000 
4.000000 23.000000 24.000000 
-3.000000 -17.000000 4.000000 
4.000000 -19.000000 6.000000 

//STUDYID 	GARCA-MART 2008		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 			
//CONDITIONID  			
//CONTRASTID  			
//controls=19
//subjects=18
-41.170601 10.886700 -4.860000 
41.175400 14.000500 -2.756100 
52.133499 -35.231300 8.776200 
-22.393400 4.111100 -16.016001 
-35.510399 7.670100 -12.272600 

//STUDYID 	HONEA 2008		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 2 SUMMARY OF THE RESULTS OBTAINED BY VOXEL-WISE WTATISTICAL ANALYSIS OF THE GM MAPS OF DECREASES IN SCZ WITH NC		
//CONDITIONID  			
//CONTRASTID  			
//controls=212
//subjects=169
-27.155701 56.099400 19.678600 
27.204201 57.533199 9.590800 
-3.058100 44.501598 44.301998 
-4.971600 28.614000 42.106300 
5.283900 39.091702 52.089001 
-2.790000 59.039600 16.585199 
-17.180201 34.622299 50.569099 
47.644699 14.963000 8.226800 
49.286999 6.267400 33.725300 
52.817402 -28.673201 44.509800 
-3.569400 30.580299 -17.291201 
-39.325100 11.522900 -1.177400 
-57.369598 -47.480000 4.724900 
-54.350800 -44.454498 -21.173300 
-19.927900 -79.464401 -11.842300 
-46.481098 -53.716400 45.871101 
49.239300 -67.952599 4.319900 
-18.042299 -88.437798 -17.953899 
20.220501 -94.273499 -7.147200 
2.649700 -20.139400 1.288000 
-30.969101 -77.498802 -35.280102 
31.712700 -78.946503 -33.768501 

//STUDYID 	HORN 2010		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	COORDINATES IN TEXT		
//CONDITIONID  			
//CONTRASTID  			
//controls=20
//subjects=20
15.000000 68.000000 4.000000 
-50.000000 8.000000 7.000000 

//STUDYID 	HUANG 2015			
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 2. BRAIN CLUSTERS WITH SIGNIFCANT GRAY MATTER VOLUME CHANGES			
//CONDITIONID  				
//CONTRASTID  				
//controls=18
//subjects=18
-43.109798 4.753900 0.945100 
2.639700 -16.598801 4.278900 
-4.874700 -16.837200 7.783300 
41.151051 19.672300 3.112900 
42.219200 -11.030150 31.808500 

//STUDYID 	HULSHOFF 2001		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 2 FOCAL GRAY MATTER DECREASES 		
//CONDITIONID  			
//CONTRASTID  			
//controls=158
//subjects=159
-15.000000 -9.000000 -15.000000 
-17.000000 -26.000000 -11.000000 
-35.000000 17.000000 -11.000000 
-35.000000 17.000000 -1.000000 
-3.000000 -19.000000 5.000000 
-1.000000 41.000000 -13.000000 
-43.000000 41.000000 13.000000 
-5.000000 24.000000 35.000000 
-39.000000 -14.000000 11.000000 
-39.000000 17.000000 -17.000000 
-1.000000 -74.000000 -1.000000 
-3.000000 -48.000000 33.000000 
-5.000000 -62.000000 17.000000 
31.000000 15.000000 -9.000000 
45.000000 12.000000 -1.000000 
1.000000 -19.000000 5.000000 
1.000000 43.000000 -13.000000 
35.000000 55.000000 5.000000 
3.000000 36.000000 37.000000 
39.000000 0.000000 7.000000 
37.000000 19.000000 -19.000000 
1.000000 -74.000000 -1.000000 
1.000000 -48.000000 33.000000 
1.000000 -60.000000 21.000000 
49.000000 -26.000000 51.000000 

//STUDYID 	HEROLD 2009		
//UNCORRECTED
//STRUCTURAL
//WB
//CENSOR=2.580000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 2. SIGNIFICANT DECREASE IN GRAY MATTER DENSITY IN PATIENTS WITH SCHIZOPHRENIA COMPARED WITH CONTROLS		
//CONDITIONID  			
//CONTRASTID  			
//controls=21
//subjects=18
12.111700 40.938000 17.114599 
9.483100 40.026299 -6.456100 
9.582600 47.402100 -15.793400 
52.537498 5.256700 -24.083799 
41.261299 -7.892300 -24.363501 
37.569000 -2.805300 -28.512199 
-46.681499 -5.329500 -26.077999 
-43.019299 -4.347500 -15.126000 
-36.557400 -12.563200 -7.585200 
-42.103001 30.044001 3.882500 
-36.557999 25.665800 10.817100 
16.848200 59.697498 18.670099 
29.324400 -15.868700 63.314301 
17.243700 -20.405399 50.175400 
6.940900 -21.346100 50.883598 
58.994801 -15.750400 -22.079300 
-14.890800 -8.514500 -24.160000 
-22.399599 49.566502 6.574700 
-45.136002 -29.566900 4.494200 
-54.329300 16.756300 5.385900 
-18.582100 42.100498 -6.614700 
-16.726700 34.643299 -8.092400 
-14.820400 50.458302 -5.000000 
-26.030899 -52.153702 -56.662800 
-16.669500 -48.532902 -55.362301 
-13.956400 -67.707397 -52.351898 
-44.918701 -33.748299 -25.623301 
36.119099 -78.991600 1.479900 
41.302200 -46.625301 -48.221199 
31.913500 -47.790298 -44.812599 
35.705200 -50.054298 -52.170601 
29.337000 -32.128101 53.890400 
-52.685501 -54.738899 0.588000 
-43.360298 -60.586700 2.033200 
-24.685200 -62.019299 6.647500 
-35.414398 52.335300 -3.282800 
-34.942402 -84.348801 -8.796300 
62.632198 -29.584200 -15.020600 

//STUDYID 	HOOKER 2011		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	WHOLE-BRAIN ANALYSIS OF BETWEEN-GROUP DIFFERENCES SHOWING REGIONS WHERE SCHIZOPHRENIA PARTICIPANTS HAVE LESS GRAY MATTER VOLUME (GMV) AS COMPARED TO HEALTHY CONTROL PARTICIPANTS (THRESHOLD: P<.05  FWE WITH 20 OXEL (160MM) CLUSTER EXTENT)		
//CONDITIONID  			
//CONTRASTID  			
//controls=17
//subjects=21
-4.542100 50.241600 -3.093300 
-51.431099 34.952202 2.362100 
33.957901 -32.741402 61.115501 
-8.595700 -73.033600 -22.027901 
-62.781700 -22.644199 -9.597500 
-51.608700 -54.233002 -17.410900 
62.530499 -6.030000 9.427300 
56.913700 6.727800 15.798500 
2.615100 43.236801 36.143101 
-4.691900 46.910400 14.690300 
-2.909700 49.639400 27.565500 

//STUDYID 	JAYAKUMAR 2005		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 1 REGIONS OF GRAY MATTER VOLUME DEFICITS IN FIRST-EPISODE  ANTIPSYCHOTIC-NARVE SCHIZOPHRENIA PATIENTS (N =18) IN COMPARISON TO MATCHED HEALTHY SUBJECTS (N =18)		
//CONDITIONID  			
//CONTRASTID  			
//controls=18
//subjects=18
25.000000 13.000000 -19.000000 
-43.000000 9.000000 -5.000000 
-47.000000 -17.000000 8.000000 
12.000000 13.000000 5.000000 
-11.000000 8.000000 5.000000 
-15.000000 -20.000000 40.000000 
-58.000000 -36.000000 47.000000 
-29.000000 65.000000 -3.000000 
-5.000000 -78.000000 -18.000000 
-64.000000 -14.000000 22.000000 

//STUDYID 	JOB 2002		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 2 THE PRIMARY VBM STUDY		
//CONDITIONID  			
//CONTRASTID  			
//controls=36
//subjects=34
3.960000 40.869999 1.640000 
3.960000 45.830002 -15.750000 
-55.439999 -4.460000 -11.550000 
-63.360001 -12.640000 19.059999 
-45.540001 -0.420000 -8.390000 
-11.880000 -0.840000 -16.780001 
-19.799999 -5.050000 -23.299999 
55.439999 -22.980000 6.680000 

//STUDYID 	KAPREK 2007		
//UNCORRECTED
//STRUCTURAL
//WB
//CENSOR=3.090000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 4 AREAS OF GREY MATTER VOLUME REDUCTION		
//CONDITIONID  			
//CONTRASTID  			
//controls=18
//subjects=22
-42.065102 51.364399 9.198900 
-30.782400 32.716400 -6.603900 
39.332199 52.532902 12.038800 
31.334400 1.902300 53.928101 
43.168301 39.792301 -6.085300 
0.426300 12.738600 62.560902 
-0.339100 31.759100 49.632198 

//STUDYID 	KAWASAKI 2004		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 2 DIAGNOSIS RELATED REGIONAL FINDINGS OF GRAY MATTER CONCENTRATION USING SPM99 T STATISTICS		
//CONDITIONID  			
//CONTRASTID  			
//controls=50
//subjects=25
4.000000 44.000000 24.000000 
-2.000000 57.000000 8.000000 
1.000000 54.000000 6.000000 
-1.000000 36.000000 26.000000 
2.000000 22.000000 41.000000 
-50.000000 15.000000 32.000000 
-31.000000 59.000000 20.000000 
-48.000000 42.000000 13.000000 
-41.000000 24.000000 -10.000000 
39.000000 27.000000 -14.000000 
-30.000000 42.000000 -21.000000 
-41.000000 -3.000000 5.000000 
-46.000000 -10.000000 8.000000 
-57.000000 -20.000000 14.000000 
-18.000000 -7.000000 -19.000000 
17.000000 -6.000000 -22.000000 
1.000000 5.000000 -3.000000 
-1.000000 54.000000 19.000000 

//STUDYID 	KAWASAKI 2007		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 2 REDUCED GRAY MATTER CONCENTRATION USING SPM99 T-STATISTIC		
//CONDITIONID  			
//CONTRASTID  			
//controls=30
//subjects=30
-3.904900 28.107700 24.928900 
5.437800 32.450298 28.994699 
4.637700 44.748402 17.333000 
-43.315601 8.140900 29.194000 
-33.699299 15.242300 -0.814800 
40.229698 17.547600 0.224500 
-44.136299 0.203400 10.497700 
36.423401 10.560800 5.037100 
-50.555401 -9.356500 -11.100900 

//STUDYID 	KUBICKI 2002		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 2 AREAS OF REDUCED REGIONAL GRAY MATTER DENSITY		
//CONDITIONID  			
//CONTRASTID  			
//controls=18
//subjects=16
38.000000 22.000000 3.000000 
-6.000000 2.000000 40.000000 
9.000000 14.000000 33.000000 
-60.000000 -28.000000 11.000000 
61.000000 -12.000000 10.000000 
-46.000000 -8.000000 12.000000 
39.000000 9.000000 4.000000 
35.000000 -34.000000 44.000000 
-18.000000 -39.000000 1.000000 

//STUDYID 	LEI 2015		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 2 VOXEL-WISE COMPARISONS OF GMV BETWEEN GROUPS		
//CONDITIONID  			
//CONTRASTID  			
//controls=84
//subjects=88
8.322100 -57.826599 -24.226101 

//STUDYID 	LIAO 2015		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 2 AREAS OF REDUCED GRAY MATTER VOLUME IN SCHIZOPHRENIC PATIENTS COMPARED WITH HEALTHY CONTROLS (P < 0.05  FWE CORRECTED  CLUSTER SIZE >20).		
//CONDITIONID  			
//CONTRASTID  			
//controls=99
//subjects=93
-0.824100 35.399799 -6.945400 
0.999900 40.370998 1.596700 
7.624500 32.885502 -11.561800 
41.092800 -10.501700 -3.814600 
38.327400 -12.792800 -10.348000 
43.970901 10.222600 -3.026000 
-42.190300 -11.802400 -4.881700 
-39.280602 5.599100 -9.774100 
-43.065399 -5.722700 -9.821000 
30.033300 10.396900 -15.809500 
-53.490601 -7.897600 6.131100 
-31.830601 23.395300 3.469400 

//STUDYID 	MARTINOT 2001		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 3 REGIONS OF REDUCED REGIONAL GRAY MATTER		
//CONDITIONID  			
//CONTRASTID  			
//controls=20
//subjects=20
-40.000000 4.000000 8.000000 
-40.000000 22.000000 2.000000 
-58.000000 3.000000 8.000000 
-8.000000 56.000000 10.000000 
-6.000000 39.000000 -12.000000 
-34.000000 -42.000000 -20.000000 
-33.000000 -51.000000 -16.000000 
-22.000000 54.000000 9.000000 

//STUDYID 	MARCELIS 2003		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 3		
//CONDITIONID  			
//CONTRASTID  			
//controls=27
//subjects=31
4.800000 18.600000 6.600000 
0.500000 17.200001 42.200001 
-35.700001 9.900000 12.900000 
-7.300000 -16.100000 7.200000 
-26.000000 -53.599998 -55.900002 
22.000000 -55.900002 -59.099998 
1.600000 3.100000 54.299999 
-38.799999 3.900000 13.000000 
3.200000 -41.099998 45.500000 
4.000000 -59.500000 21.900000 

//STUDYID 	MCINTOSH 2004		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 2. VBM ANALYSIS OF PATIENTS VERSUS CONTROLS TABLE 3. REDUCTIONS IN GRAY MATTER IN SCHIZOPHRENIC PATIENTS COMPARED WITH THEIR UNAFFECTED RELATIVES		
//CONDITIONID  			
//CONTRASTID  			
//controls=49
//subjects=71
-41.000000 12.000000 48.000000 
-34.000000 31.000000 40.000000 
-50.000000 11.000000 21.000000 
-31.000000 -48.000000 -5.000000 
-58.000000 -39.000000 20.000000 
-58.000000 -33.000000 5.000000 
-53.000000 -15.000000 36.000000 

//STUDYID 	MOLINA 2011		
//UNCORRECTED
//STRUCTURAL
//WB
//CENSOR=3.090000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 2 LOCATION  PEAK COORDINATES AND T VALUE OF THE LOCAL MAXIMA AND VOXEL EXTENT OF THE GM DIFFERENCES BETWEEN EACH PAIR OF GROUPS (P\0.001 UNCORRECTED IN ALL CASES)		
//CONDITIONID  			
//CONTRASTID  			
//controls=24
//subjects=28
-3.039500 39.227001 39.367298 
21.416100 5.749000 7.186400 

//STUDYID 	MOORHEAD 2004		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 4 NORMALIZED SPACE: NORMAL CONTROLS > SCHIZOPHRENICS		
//CONDITIONID  			
//CONTRASTID  			
//controls=29
//subjects=25
-59.064400 -3.809800 2.783300 
55.044899 -5.978000 9.344900 
6.107600 -78.570000 10.192500 
-13.597200 -96.285896 8.547400 
14.601900 33.171299 54.430901 

//STUDYID 	NAKAMURA 2013		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 2 |TALAIRACH COORDINATES FOR REGIONS OF REDUCED GRAY MATTER VOLUME IN THE SCHIZOPHRENIA PATIENTS COMPARED TO THE HEALTHY CONTROLS		
//CONDITIONID  			
//CONTRASTID  			
//controls=51
//subjects=34
-11.000000 42.000000 8.000000 

//STUDYID 	OHNISHI 2006		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 2 RESULTS OF IMAGE ANALYSES		
//CONDITIONID  			
//CONTRASTID  			
//controls=76
//subjects=47
33.000000 11.000000 -2.000000 
-33.000000 11.000000 4.000000 
30.000000 1.000000 -17.000000 
30.000000 -41.000000 -8.000000 
-20.000000 -41.000000 -8.000000 
9.000000 33.000000 20.000000 
-11.000000 32.000000 20.000000 
-12.000000 -16.000000 39.000000 
27.000000 28.000000 -11.000000 
12.000000 43.000000 39.000000 
-8.000000 47.000000 19.000000 
-44.000000 23.000000 15.000000 
-30.000000 24.000000 43.000000 
-35.000000 17.000000 51.000000 
41.000000 13.000000 45.000000 
47.000000 -23.000000 -1.000000 
56.000000 -15.000000 3.000000 
-36.000000 1.000000 -17.000000 
-15.000000 -17.000000 2.000000 

//STUDYID 	SALGADO-PINEDA 2003		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=3.090000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 3 VBM STUDY: GM DECREASES IN SCHIZOPHRENIA PATIENTS		
//CONDITIONID  			
//CONTRASTID  			
//controls=13
//subjects=13
-12.000000 10.000000 11.000000 
-12.000000 -28.000000 56.000000 
-5.000000 -18.000000 8.000000 
5.000000 -16.000000 8.000000 
12.000000 10.000000 10.000000 
11.000000 18.000000 1.000000 
-9.000000 -51.000000 -10.000000 
9.000000 24.000000 33.000000 
10.000000 32.000000 25.000000 
-29.000000 -53.000000 -10.000000 
-32.000000 -20.000000 -16.000000 
-32.000000 -35.000000 -10.000000 
31.000000 2.000000 1.000000 
-43.000000 19.000000 -7.000000 
-3.000000 -69.000000 -19.000000 

//STUDYID 	SALGADO-PINEDA 2004		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 			
//CONDITIONID  			
//CONTRASTID  			
//controls=14
//subjects=14
40.000000 55.000000 18.000000 
50.000000 40.000000 22.000000 
31.000000 65.000000 -1.000000 
12.000000 19.000000 46.000000 
-5.000000 63.000000 -14.000000 
-50.000000 15.000000 36.000000 
-43.000000 54.000000 14.000000 
-36.000000 64.000000 13.000000 
-12.000000 34.000000 42.000000 
-40.000000 15.000000 45.000000 
51.000000 -82.000000 15.000000 
60.000000 -63.000000 11.000000 
56.000000 -25.000000 52.000000 
64.000000 -23.000000 28.000000 
-60.000000 -61.000000 10.000000 
-64.000000 -28.000000 24.000000 
-50.000000 -39.000000 56.000000 
-63.000000 -14.000000 16.000000 
-45.000000 -45.000000 32.000000 
52.000000 -50.000000 -15.000000 
46.000000 -16.000000 -27.000000 
-63.000000 -22.000000 -19.000000 
-66.000000 -3.000000 -9.000000 
10.000000 -1.000000 40.000000 
-8.000000 10.000000 35.000000 
-4.000000 17.000000 22.000000 
26.000000 -23.000000 -16.000000 
26.000000 -46.000000 -6.000000 
-10.000000 -20.000000 -16.000000 
20.000000 -18.000000 12.000000 
-18.000000 -19.000000 17.000000 
-16.000000 -20.000000 1.000000 
16.000000 -14.000000 23.000000 
-4.000000 12.000000 -2.000000 
-49.000000 -20.000000 -26.000000 
-34.000000 -42.000000 -18.000000 
47.000000 -30.000000 -22.000000 
-55.000000 -55.000000 -25.000000 

//STUDYID 	SHAPLESKE 2002		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 3 REGIONAL PROPORTIONAL TISSUE VOLUME DIFFERENCES BETWEEN SCHIZOPHRENIA PATIENTS (COMBINED) VERSUS CONTROLS		
//CONDITIONID  			
//CONTRASTID  			
//controls=32
//subjects=72
-2.000000 28.000000 -15.000000 
17.000000 -2.000000 -25.000000 
-42.000000 -3.000000 8.000000 
3.000000 -4.000000 4.000000 
-20.000000 -8.000000 -15.000000 
41.000000 -8.000000 3.000000 
-4.000000 -66.000000 32.000000 
3.000000 -67.000000 24.000000 
-3.000000 -67.000000 23.000000 

//STUDYID 	SIGMUNDSSON 2001		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 3. GRAY REGIONAL DIFFERENCES BETWEEN SCHIZOPHRENIC PATIENTS WITH PROMINENT NEGATIVE SYMPTOMS (N=27) AND HEALTHY COMPARISON SUBJECTS (N=27)		
//CONDITIONID  			
//CONTRASTID  			
//controls=27
//subjects=27
-38.000000 -4.000000 -7.000000 
-0.500000 46.000000 1.000000 
-29.000000 -6.000000 -26.000000 
-26.000000 -3.600000 -12.000000 

//STUDYID 	STEGMAYER 2014		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 3 REGIONS WITH SIGNIFICANT GROUP DIFFERENCES IN BRAIN DENSITY (ALL PATIENTS B HEALTHY CONTROLS)		
//CONDITIONID  			
//CONTRASTID  			
//controls=34
//subjects=43
8.167500 -17.509001 15.101100 
-23.256500 32.160400 -11.976900 
-4.510700 37.813202 -13.113100 
2.983700 45.132801 -10.635700 
8.488700 54.917000 8.262500 
-25.056299 14.688200 -29.642099 

//STUDYID 	SUZUKI 2002		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 1. BRAIN REGIONS IN WHICH VOXELS SHOWED SIGNIFICANT REGIONAL GRAY MATTER CHANGES IN PATIENTS WITH SCHIZOPHRENIA COMPARED WITH CONTROLS		
//CONDITIONID  			
//CONTRASTID  			
//controls=42
//subjects=45
-52.000000 10.000000 32.000000 
4.000000 30.000000 28.000000 
30.000000 -22.000000 -14.000000 
50.000000 42.000000 6.000000 
-18.000000 -6.000000 -20.000000 
-52.000000 8.000000 34.000000 
-4.000000 32.000000 28.000000 
0.000000 36.000000 22.000000 
32.000000 56.000000 14.000000 

//STUDYID 	TAE HYON HA 2004		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 2 REGIONS OF REDUCED GRAY MATTER CONCENTRATIONS N PATIENTS WITH PARANOID SCHIZOPHRENIA COMPARED WITH CONTROLS		
//CONDITIONID  			
//CONTRASTID  			
//controls=35
//subjects=35
4.000000 50.000000 -8.000000 
0.000000 42.000000 14.000000 
2.000000 9.000000 -12.000000 
-41.000000 19.000000 -1.000000 
-50.000000 -5.000000 2.000000 
-44.000000 -9.000000 6.000000 
-48.000000 -19.000000 -28.000000 
59.000000 16.000000 7.000000 
50.000000 10.000000 -4.000000 
40.000000 21.000000 -9.000000 
65.000000 -27.000000 0.000000 
-34.000000 53.000000 18.000000 
-34.000000 56.000000 1.000000 

//STUDYID 	WANG 2017		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 2 REGIONS SHOWING GRAY MATTER DENSITY AMONG SZ-NCD  SZ-CD  AND CONTROL GROUP		
//CONDITIONID  			
//CONTRASTID  			
//controls=21
//subjects=34
-10.996300 -49.797699 -63.521198 
62.518902 -9.788400 9.126500 
-25.361700 6.146600 5.774700 
-11.259700 18.554300 3.320000 
-20.512100 -3.995300 -21.155701 
-40.167198 -53.072601 -44.263500 

//STUDYID 	WHITFORD 2005		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 1. DESCRIPTIVE DETAILS OF THE FOUR REGIONS OF GREY MATTER VOLUME REDUCTION IN 31 PATIENTS WITH FIRST EPISODE SCHIZOPHRENIA RELATIVE TO MATCHED HEALTHY CONTROLS (P < 0.05 CORRECTED FOR MULTIPLE COMPARISONS  EXTENT THRESHOLD = 400 VOXELS)	
//CONDITIONID  			
//CONTRASTID  			
//controls=30
//subjects=31
-29.000000 52.000000 -3.000000 
-9.000000 46.000000 3.000000 
-9.000000 41.000000 14.000000 
-65.000000 -27.000000 14.000000 
-55.000000 -18.000000 45.000000 
-59.000000 -24.000000 40.000000 
29.000000 -50.000000 -32.000000 
33.000000 -59.000000 -32.000000 
44.000000 -45.000000 -28.000000 
56.000000 -12.000000 45.000000 
64.000000 -10.000000 19.000000 
61.000000 3.000000 16.000000 

//STUDYID 	WHITFORD 2006		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 2. BASELINE STUDYREGIONS WHERE THE 41 FES PATIENTS HAD LESS GM AT BASELINE THAN DID THE 47 MATCHED HEALTHY CONTROLS (STATISTICALLY CONTROLLING FOR AGE  GENDER  HANDEDNESS  AND GLOBAL GM VOLUME)		
//CONDITIONID  			
//CONTRASTID  			
//controls=47
//subjects=41
64.000000 -2.000000 27.000000 
61.000000 7.000000 26.000000 
60.000000 -11.000000 42.000000 
30.000000 -60.000000 -4.000000 
-32.000000 51.000000 -7.000000 
-27.000000 52.000000 8.000000 
-38.000000 43.000000 -6.000000 
-62.000000 21.000000 37.000000 
-60.000000 -15.000000 41.000000 
-68.000000 -32.000000 -3.000000 
-17.000000 25.000000 -14.000000 
-26.000000 28.000000 -13.000000 
-11.000000 36.000000 17.000000 
39.000000 -42.000000 -27.000000 

//STUDYID 	WILKE 2001		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=3.090000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 2 TALAIRACH COORDINATES OF SIGNIFICANT CLUSTERS		
//CONDITIONID  			
//CONTRASTID  			
//controls=48
//subjects=48
59.000000 7.000000 -9.000000 
51.000000 14.000000 -23.000000 
59.000000 6.000000 -5.000000 
63.000000 0.000000 -3.000000 
-65.000000 -7.000000 6.000000 
-44.000000 16.000000 1.000000 
-40.000000 19.000000 -9.000000 
-50.000000 31.000000 -8.000000 
-4.000000 45.000000 -24.000000 
-2.000000 56.000000 1.000000 
-2.000000 54.000000 -6.000000 

//STUDYID 	WRIGHT 1999		
//UNCORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 3.AREAS OF REDUCED REGIONALGREY MATTERINSCHIZOPHRENICSCOMPARED WITH CONTROLS		
//CONDITIONID  			
//CONTRASTID  			
//controls=15
//subjects=15
-28.000000 12.000000 -20.000000 
-46.000000 14.000000 36.000000 
-46.000000 14.000000 0.000000 
-48.000000 6.000000 -4.000000 
-34.000000 16.000000 -12.000000 
28.000000 12.000000 -20.000000 
44.000000 8.000000 -8.000000 
42.000000 18.000000 0.000000 
24.000000 -12.000000 -12.000000 

//STUDYID 	XU 2009		
//UNCORRECTED
//STRUCTURAL
//WB
//CENSOR=3.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE II TALAIRACH LABELS FOR THE RESULT OF VBM		
//CONDITIONID  			
//CONTRASTID  			
//controls=120
//subjects=120
-6.697000 -9.956600 4.702300 
5.495900 -9.750700 1.249400 
-34.688499 4.695400 1.037800 
30.814899 7.926200 2.956300 
-32.773701 14.223600 0.017000 
36.492599 14.900000 -1.835700 
-32.814098 10.174800 3.303000 
30.855301 11.975000 -0.329700 
-34.628101 1.663000 -8.230000 
29.968300 0.637900 -12.078000 
-12.675500 -12.680600 50.447399 
5.741800 42.798500 -5.375000 
-29.000900 3.575800 -8.914500 
18.560699 -30.222500 -3.847600 
-55.468601 -10.780200 18.513901 
51.193901 -16.146601 18.415400 
-58.070000 -18.700500 -11.935300 
57.041302 -17.475599 -12.311400 
-27.090700 0.312600 -15.471600 
27.264700 -6.492200 -28.926300 
-27.612101 -75.952797 15.427500 
27.584101 -77.348503 16.856701 
-24.232700 23.565300 -10.870600 
39.377899 35.696899 -1.943800 
-12.673300 -43.610600 35.336800 
9.864900 -8.352200 42.028400 
-28.924999 50.769402 3.887700 
13.815900 31.956200 34.467602 
-9.310000 43.910500 5.371000 
8.272200 29.975000 24.316500 
-60.911701 -20.850599 -8.529800 
35.972500 -67.724800 25.846901 
-56.382599 -6.003100 17.982901 
44.795700 8.187500 10.359600 
-21.976200 -71.221199 14.968600 
23.871599 -74.285896 14.351000 
-32.361900 -44.776699 39.528801 
48.235001 -44.968498 24.198799 
-3.586500 38.601101 -11.234200 
16.987200 30.146900 -13.477800 
7.990400 -83.930199 6.175100 
7.633200 35.704300 -11.336200 
-40.522301 -30.252800 12.616000 
56.838402 -13.149000 16.012699 
-29.512400 -80.782997 16.824301 
29.419500 -77.724503 21.360800 
-44.528000 -70.202400 27.425600 
35.012199 -73.428497 26.282101 
-38.673500 -76.011597 -6.367300 
29.619600 -78.437897 -4.869100 
22.451099 4.012700 -6.479400 
-52.801899 -44.988300 20.321100 
44.461899 -47.979099 26.622101 
-40.916100 -65.175797 46.823898 
-53.325199 -15.333400 -18.831800 

//STUDYID 	ZHANG 2017		
//CORRECTED
//STRUCTURAL
//WB
//CENSOR=0.000000
//COVARIATE=0.000000
//DESCRIPTION 	TABLE 2. GRAY MATTER VOLUME COMPARISON BETWEEN DRUG-NAVE  FRST-EPISODE SCHIZOPHRENIA PATIENTS AND HEALTHY CONTROLS		
//CONDITIONID  			
//CONTRASTID  			
//controls=83
//subjects=75
-11.006300 -42.043201 62.559200 
-13.811900 -39.277500 63.650600 
-14.664800 -5.663200 69.037598 
34.007198 -16.768200 62.393902 
49.437401 -28.630400 -2.460600 
27.707701 -87.026497 -3.773100 
11.782000 -90.747002 -3.352300 
2.717800 -65.880997 -29.448200 

